Prognostic value and prospective molecular mechanism of miR‑100‑5p in hepatocellular carcinoma: A comprehensive study based on 1,258 samples
- Authors:
- Qing‑Lin He
- Shan‑Yu Qin
- Lin Tao
- Hong‑Jian Ning
- Hai‑Xing Jiang
-
Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China - Published online on: October 4, 2019 https://doi.org/10.3892/ol.2019.10962
- Pages: 6126-6142
-
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kudo M: Systemic therapy for hepatocellular carcinoma: 2017 update. Oncology. 93 (Suppl 1):S135–S146. 2017. View Article : Google Scholar | |
Aguilar C, Mano M and Eulalio A: MicroRNAs at the Host-bacteria interface: Host defense or bacterial offense. Trends Microbiol. 27:206–218. 2019. View Article : Google Scholar : PubMed/NCBI | |
Mollaei H, Safaralizadeh R and Rostami Z: MicroRNA replacement therapy in cancer. J Cell Physiol. 234:12369–12384. 2019. View Article : Google Scholar : PubMed/NCBI | |
Li TT, Gao X, Gao L, Gan BL, Xie ZC, Zeng JJ and Chen G: Role of upregulated miR-136-5p in lung adenocarcinoma: A study of 1242 samples utilizing bioinformatics analysis. Pathol Res Pract. 214:750–766. 2018. View Article : Google Scholar : PubMed/NCBI | |
Gao L, Li SH, Tian YX, Zhu QQ, Chen G, Pang YY and Hu XH: Role of downregulated miR-133a-3p expression in bladder cancer: A bioinformatics study. Onco Targets Ther. 10:3667–3683. 2017. View Article : Google Scholar : PubMed/NCBI | |
He D, Yue Z, Li G, Chen L, Feng H and Sun J: Low serum levels of miR-101 are associated with poor prognosis of colorectal cancer patients after curative resection. Med Sci Monit. 24:7475–7481. 2018. View Article : Google Scholar : PubMed/NCBI | |
Zheng Y, Tan K and Huang H: Long noncoding RNA HAGLROS regulates apoptosis and autophagy in colorectal cancer cells via sponging miR-100 to target ATG5 expression. J Cell Biochem. 120:3922–3933. 2019. View Article : Google Scholar : PubMed/NCBI | |
Wu G, Zhou W, Pan X, Sun Y, Xu H, Shi P, Li J, Gao L and Tian X: miR-100 reverses cisplatin resistance in breast cancer by suppressing HAX-1. Cell Physiol Biochem. 47:2077–2087. 2018. View Article : Google Scholar : PubMed/NCBI | |
Sun X, Liu X, Wang Y, Yang S, Chen Y and Yuan T: miR-100 inhibits the migration and invasion of nasopharyngeal carcinoma by targeting IGF1R. Oncol Lett. 15:8333–8338. 2018.PubMed/NCBI | |
Shi DB, Wang YW, Xing AY, Gao JW, Zhang H, Guo XY and Gao P: C/EBPα-induced miR-100 expression suppresses tumor metastasis and growth by targeting ZBTB7A in gastric cancer. Cancer Lett. 369:376–385. 2015. View Article : Google Scholar : PubMed/NCBI | |
Chen P, Zhao X and Ma L: Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma. Mol Cell Biochem. 383:49–58. 2013. View Article : Google Scholar : PubMed/NCBI | |
Zhou HC, Fang JH, Luo X, Zhang L, Yang J, Zhang C and Zhuang SM: Downregulation of microRNA-100 enhances the ICMT-Rac1 signaling and promotes metastasis of hepatocellular carcinoma cells. Oncotarget. 5:12177–12188. 2014. View Article : Google Scholar : PubMed/NCBI | |
Zhou HC, Fang JH, Shang LR, Zhang ZJ, Sang Y, Xu L, Yuan Y, Chen MS, Zheng L, Zhang Y and Zhuang SM: MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters. J Pathol. 240:450–460. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ge YY, Shi Q, Zheng ZY, Gong J, Zeng C, Yang J and Zhuang SM: MicroRNA-100 promotes the autophagy of hepatocellular carcinoma cells by inhibiting the expression of mTOR and IGF-1R. Oncotarget. 5:6218–6228. 2014. View Article : Google Scholar : PubMed/NCBI | |
Pan WY, Zeng JH, Wen DY, Wang JY, Wang PP, Chen G and Feng ZB: Oncogenic value of microRNA-15b-5p in hepatocellular carcinoma and a bioinformatics investigation. Oncol Lett. 17:1695–1713. 2019.PubMed/NCBI | |
Zhang S, Gao Y and Huang J: Interleukin-8 Gene-251 A/T (rs4073) polymorphism and coronary artery disease risk: A meta-analysis. Med Sci Monit. 25:1645–1655. 2019. View Article : Google Scholar : PubMed/NCBI | |
Zhang X, Xin G and Sun D: Serum exosomal miR-328, miR-575, miR-134 and miR-671-5p as potential biomarkers for the diagnosis of Kawasaki disease and the prediction of therapeutic outcomes of intravenous immunoglobulin therapy. Exp Ther Med. 16:2420–2432. 2018.PubMed/NCBI | |
Betel D, Koppal A, Agius P, Sander C and Leslie C: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11:R902010. View Article : Google Scholar : PubMed/NCBI | |
Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, Filippidis C, Dalamagas T and Hatzigeorgiou AG: DIANA-microT web server v5.0: Service integration into miRNA functional analysis workflows. Nucleic Acids Res. 41:W169–W173. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hsu SD, Chu CH, Tsou AP, Chen SJ, Chen HC, Hsu PW, Wong YH, Chen YH, Chen GH and Huang HD: miRNAMap 2.0: Genomic maps of microRNAs in metazoan genomes. Nucleic Acids Res 36 (Database Issue). D165–D169. 2008. | |
Tsang JS, Ebert MS and van Oudenaarden A: Genome-wide dissection of microRNA functions and cotargeting networks using gene set signatures. Mol Cell. 38:140–153. 2010. View Article : Google Scholar : PubMed/NCBI | |
Vejnar CE, Blum M and Zdobnov EM: miRmap web: Comprehensive microRNA target prediction online. Nucleic Acids Res. 41:W165–W168. 2013. View Article : Google Scholar : PubMed/NCBI | |
Anders G, Mackowiak SD, Jens M, Maaskola J, Kuntzagk A, Rajewsky N, Landthaler M and Dieterich C: doRiNA: A database of RNA interactions in post-transcriptional regulation. Nucleic Acids Res 40 (Database Issue). D180–D186. 2012. View Article : Google Scholar | |
Kertesz M, Iovino N, Unnerstall U, Gaul U and Segal E: The role of site accessibility in microRNA target recognition. Nat Genet. 39:1278–1284. 2007. View Article : Google Scholar : PubMed/NCBI | |
Wang X and El Naqa IM: Prediction of both conserved and nonconserved microRNA targets in animals. Bioinformatics. 24:325–332. 2008. View Article : Google Scholar : PubMed/NCBI | |
Rehmsmeier M, Steffen P, Hochsmann M and Giegerich R: Fast and effective prediction of microRNA/target duplexes. RNA. 10:1507–1517. 2004. View Article : Google Scholar : PubMed/NCBI | |
Loher P and Rigoutsos I: Interactive exploration of RNA22 microRNA target predictions. Bioinformatics. 28:3322–3323. 2012. View Article : Google Scholar : PubMed/NCBI | |
Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI | |
Calderón-González KG, Hernández-Monge J, Herrera-Aguirre ME and Luna-Arias JP: Bioinformatics tools for proteomics data interpretation. Adv Exp Med Biol. 919:281–341. 2016. View Article : Google Scholar : PubMed/NCBI | |
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al: The STRING database in 2017: Quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 45:D362–D368. 2017. View Article : Google Scholar : PubMed/NCBI | |
Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, Thorgeirsson SS, Sun Z, Tang ZY, Qin LX and Wang XW: A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res. 70:10202–10212. 2010. View Article : Google Scholar : PubMed/NCBI | |
Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, et al: Gene expression patterns in human liver cancers. Mol Biol Cell. 13:1929–1939. 2002. View Article : Google Scholar : PubMed/NCBI | |
Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et al: A pathology atlas of the human cancer transcriptome. Science. 357(pii): eaan25072017. View Article : Google Scholar : PubMed/NCBI | |
Jiao XD, Qin BD, You P, Cai J and Zang YS: The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base. Lung Cancer. 123:70–75. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ryan M, Wong WC, Brown R, Akbani R, Su X, Broom B, Melott J and Weinstein J: TCGASpliceSeq a compendium of alternative mRNA splicing in cancer. Nucleic Acids Res. 44:D1018–D1022. 2016. View Article : Google Scholar : PubMed/NCBI | |
Zhang R, Lin P, Yang X, He RQ, Wu HY, Dang YW, Gu YY, Peng ZG, Feng ZB and Chen G: Survival associated alternative splicing events in diffuse large B-cell lymphoma. Am J Transl Res. 10:2636–2647. 2018.PubMed/NCBI | |
Li Y, Sun N, Lu Z, Sun S, Huang J, Chen Z and He J: Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett. 393:40–51. 2017. View Article : Google Scholar : PubMed/NCBI | |
Xiao F, Bai Y, Chen Z, Li Y, Luo L, Huang J, Yang J, Liao H and Guo L: Downregulation of HOXA1 gene affects small cell lung cancer cell survival and chemoresistance under the regulation of miR-100. Eur J Cancer. 50:1541–1554. 2014. View Article : Google Scholar : PubMed/NCBI | |
Guo P, Xiong X, Zhang S and Peng D: miR-100 resensitizes resistant epithelial ovarian cancer to cisplatin. Oncol Rep. 36:3552–3558. 2016. View Article : Google Scholar : PubMed/NCBI | |
Qin X, Yu S, Zhou L, Shi M, Hu Y, Xu X, Shen B, Liu S, Yan D and Feng J: Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner. Int J Nanomedicine. 12:3721–3733. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wang M, Ren D, Guo W, Wang Z, Huang S, Du H, Song L and Peng X: Loss of miR-100 enhances migration, invasion, epithelial-mesenchymal transition and stemness properties in prostate cancer cells through targeting Argonaute 2. Int J Oncol. 45:362–372. 2014. View Article : Google Scholar : PubMed/NCBI | |
Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, Sañudo A, Antunes AA and Srougi M: Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol. 29:265–269. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhang H, Wang J, Wang Z, Ruan C, Wang L and Guo H: Serum miR-100 is a potential biomarker for detection and outcome prediction of glioblastoma patients. Cancer Biomark. 24:43–49. 2019. View Article : Google Scholar : PubMed/NCBI | |
Azizmohammadi S, Azizmohammadi S, Safari A, Kosari N, Kaghazian M, Yahaghi E and Seifoleslami M: The role and expression of miR-100 and miR-203 profile as prognostic markers in epithelial ovarian cancer. Am J Transl Res. 8:2403–2410. 2016.PubMed/NCBI | |
Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, Ghiso E, Benetti A, Barlati S, Ledda-Columbano GM, et al: Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene. 31:4517–4526. 2012. View Article : Google Scholar : PubMed/NCBI | |
Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP and Odenthal M: MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology. 47:1223–1232. 2008. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Gao Y, Shi W, Zhai D, Rao Q, Jia X, Liu J, Jiao X and Du Z: Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma. Cancer Biomark. 15:171–180. 2015. View Article : Google Scholar : PubMed/NCBI | |
Tsai CT, Zulueta MML and Hung SC: Synthetic heparin and heparan sulfate: Probes in defining biological functions. Curr Opin Chem Biol. 40:152–159. 2017. View Article : Google Scholar : PubMed/NCBI | |
Li JP and Kusche-Gullberg M: Heparan Sulfate: Biosynthesis, structure, and function. Int Rev Cell Mol Biol. 325:215–273. 2016. View Article : Google Scholar : PubMed/NCBI | |
Weiss RJ, Esko JD and Tor Y: Targeting heparin and heparan sulfate protein interactions. Org Biomol Chem. 15:5656–5668. 2017. View Article : Google Scholar : PubMed/NCBI | |
Cassinelli G, Zaffaroni N and Lanzi C: The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomas. Cancer Lett. 382:245–254. 2016. View Article : Google Scholar : PubMed/NCBI | |
Ling L, Tan SK, Goh TH, Cheung E, Nurcombe V, van Wijnen AJ and Cool SM: Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy. Mol Cancer. 14:1362015. View Article : Google Scholar : PubMed/NCBI | |
Dudás J, Bocsi J, Fullár A, Baghy K, Füle T, Kudaibergenova S and Kovalszky I: Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action. Biomed Res Int. 2014:7657942014. View Article : Google Scholar : PubMed/NCBI | |
Gao J, Wang Y, Li W, Zhang J, Che Y, Cui X, Sun B and Zhao G: Loss of histone deacetylase 2 inhibits oxidative stress induced by high glucose via the HO-1/SIRT1 pathway in endothelial progenitor cells. Gene. 678:1–7. 2018. View Article : Google Scholar : PubMed/NCBI | |
Li Y, Zhou M, Lv X, Song L, Zhang D, He Y, Wang M, Zhao X, Yuan X, Shi G and Wang D: Reduced activity of HDAC3 and increased acetylation of histones H3 in peripheral blood mononuclear cells of patients with rheumatoid arthritis. J Immunol Res. 2018:73135152018. View Article : Google Scholar : PubMed/NCBI | |
Li S, Wang F, Qu Y, Chen X, Gao M, Yang J, Zhang D, Zhang N, Li W and Liu H: HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells. Oncol Lett. 13:403–409. 2017. View Article : Google Scholar : PubMed/NCBI | |
Peng Z, Zhou W, Zhang C, Liu H and Zhang Y: Curcumol controls choriocarcinoma stem-like cells self-renewal via repression of DNA Methyltransferase (DNMT)- and histone deacetylase (HDAC)-mediated epigenetic regulation. Med Sci Monit. 24:461–472. 2018. View Article : Google Scholar : PubMed/NCBI | |
Liu L, Lin W, Zhang Q, Cao W and Liu Z: TGF-β induces miR-30d down-regulation and podocyte injury through Smad2/3 and HDAC3-associated transcriptional repression. J Mol Med (Berl). 94:291–300. 2016. View Article : Google Scholar : PubMed/NCBI | |
Mao QD, Zhang W, Zhao K, Cao B, Yuan H, Wei LZ, Song MQ and Liu XS: MicroRNA-455 suppresses the oncogenic function of HDAC2 in human colorectal cancer. Braz J Med Biol Res. 50:e61032017. View Article : Google Scholar : PubMed/NCBI | |
Yang Y, Zhang J, Wu T, Xu X, Cao G, Li H and Chen X: Histone deacetylase 2 regulates the doxorubicin (Dox) resistance of hepatocarcinoma cells and transcription of ABCB1. Life Sci. 216:200–206. 2019. View Article : Google Scholar : PubMed/NCBI | |
Zhao H, Yu Z, Zhao L, He M, Ren J, Wu H, Chen Q, Yao W and Wei M: HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy. Jpn J Clin Oncol. 46:893–902. 2016. View Article : Google Scholar : PubMed/NCBI | |
Cui Z, Xie M, Wu Z and Shi Y: Relationship between histone deacetylase 3 (HDAC3) and breast cancer. Med Sci Monit. 24:2456–2464. 2018. View Article : Google Scholar : PubMed/NCBI | |
Wu LM, Yang Z, Zhou L, Zhang F, Xie HY, Feng XW, Wu J and Zheng SS: Identification of histone deacetylase 3 as a biomarker for tumor recurrence following liver transplantation in HBV-associated hepatocellular carcinoma. PLoS One. 5:e144602010. View Article : Google Scholar : PubMed/NCBI | |
Lebiedzinska-Arciszewska M, Oparka M, Vega-Naredo I, Karkucinska-Wieckowska A, Pinton P, Duszynski J and Wieckowski MR: The interplay between p66Shc, reactive oxygen species and cancer cell metabolism. Eur J Clin Invest. 45 (Suppl 1):S25–S31. 2015. View Article : Google Scholar | |
Wong N, Chan A, Lee SW, Lam E, To KF, Lai PB, Li XN, Liew CT and Johnson PJ: Positional mapping for amplified DNA sequences on 1q21-q22 in hepatocellular carcinoma indicates candidate genes over-expression. J Hepatol. 38:298–306. 2003. View Article : Google Scholar : PubMed/NCBI | |
Kisielow M, Kleiner S, Nagasawa M, Faisal A and Nagamine Y: Isoform-specific knockdown and expression of adaptor protein ShcA using small interfering RNA. Biochem J. 363:1–5. 2002. View Article : Google Scholar : PubMed/NCBI | |
Zhang L, Zhu S, Shi X and Sha W: The silence of p66(Shc) in HCT8 cells inhibits the viability via PI3K/AKT/Mdm-2/p53 signaling pathway. Int J Clin Exp Pathol. 8:9097–9104. 2015.PubMed/NCBI | |
Yukimasa S, Masaki T, Yoshida S, Uchida N, Watanabe S, Usuki H, Yoshiji H, Maeta T, Ebara K, Nakatsu T, et al: Enhanced expression of p46 Shc in the nucleus and p52 Shc in the cytoplasm of human gastric cancer. Int J Oncol. 26:905–911. 2005.PubMed/NCBI | |
Muniyan S, Chou YW, Tsai TJ, Thomes P, Veeramani S, Benigno BB, Walker LD, McDonald JF, Khan SA, Lin FF, et al: p66Shc longevity protein regulates the proliferation of human ovarian cancer cells. Mol Carcinog. 54:618–631. 2015. View Article : Google Scholar : PubMed/NCBI | |
Rajendran M, Thomes P, Zhang L, Veeramani S and Lin MF: p66Shc-a longevity redox protein in human prostate cancer progression and metastasis: p66Shc in cancer progression and metastasis. Cancer Metastasis Rev. 29:207–222. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yoshida S, Kornek M, Ikenaga N, Schmelzle M, Masuzaki R, Csizmadia E, Wu Y, Robson SC and Schuppan D: Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology. 58:1667–1680. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bid HK, Roberts RD, Manchanda PK and Houghton PJ: RAC1: An emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther. 12:1925–1934. 2013. View Article : Google Scholar : PubMed/NCBI | |
Cheng H, Wang W, Wang G, Wang A, Du L and Lou W: Silencing ras-related C3 botulinum toxin substrate 1 inhibits growth and migration of hypopharyngeal squamous cell carcinoma via the P38 mitogen-activated protein kinase signaling pathway. Med Sci Monit. 24:768–781. 2018. View Article : Google Scholar : PubMed/NCBI | |
Liu B, Xiong J, Liu G, Wu J, Wen L, Zhang Q and Zhang C: High expression of Rac1 is correlated with partial reversed cell polarity and poor prognosis in invasive ductal carcinoma of the breast. Tumour Biol. 39:10104283177109082017. View Article : Google Scholar : PubMed/NCBI | |
Yoon C, Cho SJ, Chang KK, Park DJ, Ryeom SW and Yoon SS: Role of Rac1 pathway in epithelial-to-mesenchymal transition and cancer stem-like cell phenotypes in gastric adenocarcinoma. Mol Cancer Res. 15:1106–1116. 2017. View Article : Google Scholar : PubMed/NCBI | |
Niu X, Gao Z, Qi S, Su L, Yang N, Luan X, Li J, Zhang Q, An Y and Zhang S: Macropinocytosis activated by oncogenic Dbl enables specific targeted delivery of Tat/pDNA nano-complexes into ovarian cancer cells. Int J Nanomedicine. 13:4895–4911. 2018. View Article : Google Scholar : PubMed/NCBI | |
Poudel KR, Roh-Johnson M, Su A, Ho T, Mathsyaraja H, Anderson S, Grady WM, Moens CB, Conacci-Sorrell M, Eisenman RN and Bai J: Competition between TIAM1 and membranes balances endophilin A3 activity in cancer metastasis. Dev Cell. 45:738–752.e6. 2018. View Article : Google Scholar : PubMed/NCBI | |
Aspenström P: Activated Rho GTPases in cancer-the beginning of a new paradigm. Int J Mol Sci. 19(pii): E39492018. View Article : Google Scholar : PubMed/NCBI | |
Ching YP, Leong VY, Lee MF, Xu HT, Jin DY and Ng IO: P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res. 67:3601–3608. 2007. View Article : Google Scholar : PubMed/NCBI | |
Zhu S, Jin J, Gokhale S, Lu AM, Shan H, Feng J and Xie P: Genetic alterations of TRAF proteins in human cancers. Front Immunol. 9:21112018. View Article : Google Scholar : PubMed/NCBI | |
Reder H, Wagner S, Gamerdinger U, Sandmann S, Wuerdemann N, Braeuninger A, Dugas M, Gattenloehner S, Klussmann JP and Wittekindt C: Genetic alterations in human papillomavirus-associated oropharyngeal squamous cell carcinoma of patients with treatment failure. Oral Oncol. 93:59–65. 2019. View Article : Google Scholar : PubMed/NCBI | |
Sajnani K, Islam F, Smith RA, Gopalan V and Lam AK: Genetic alterations in Krebs cycle and its impact on cancer pathogenesis. Biochimie. 135:164–172. 2017. View Article : Google Scholar : PubMed/NCBI | |
Jonckheere N, Vasseur R and Van Seuningen I: The cornerstone K-RAS mutation in pancreatic adenocarcinoma: From cell signaling network, target genes, biological processes to therapeutic targeting. Crit Rev Oncol Hematol. 111:7–19. 2017. View Article : Google Scholar : PubMed/NCBI | |
Song X, Zeng Z, Wei H and Wang Z: Alternative splicing in cancers: From aberrant regulation to new therapeutics. Semin Cell Dev Biol. 75:13–22. 2018. View Article : Google Scholar : PubMed/NCBI | |
Climente-González H, Porta-Pardo E, Godzik A and Eyras E: The functional impact of alternative splicing in cancer. Cell Rep. 20:2215–2226. 2017. View Article : Google Scholar : PubMed/NCBI | |
Xie M, Dart DA, Owen S, Wen X, Ji J and Jiang W: Insights into roles of the miR-1, −133 and −206 family in gastric cancer (Review). Oncol Rep. 36:1191–1198. 2016. View Article : Google Scholar : PubMed/NCBI | |
Teplyuk NM, Uhlmann EJ, Gabriely G, Volfovsky N, Wang Y, Teng J, Karmali P, Marcusson E, Peter M, Mohan A, et al: Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: First steps toward the clinic. EMBO Mol Med. 8:268–287. 2016. View Article : Google Scholar : PubMed/NCBI | |
Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, et al: Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer. 123:1616–1622. 2008. View Article : Google Scholar : PubMed/NCBI | |
Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y and Zhuang SM: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res. 69:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI | |
Burchard J, Zhang C, Liu AM, Poon RT, Lee NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al: microRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma. Mol Sys Biol. 6:4022010. View Article : Google Scholar | |
Sato F, Hatano E, Kitamura K, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S and Shimizu K: MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria. PLoS One. 6:e164352011. View Article : Google Scholar : PubMed/NCBI | |
Noh JH, Chang YG, Kim MG, Jung KH, Kim JK, Bae HJ, Eun JW, Shen Q, Kim SJ, Kwon SH, et al: MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett. 335:455–462. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wang PR, Xu M, Toffanin S, Li Y, Llovet JM and Russell DW: Induction of hepatocellular carcinoma by in vivo gene targeting. Proc Natl Acad Sci USA. 109:11264–11269. 2012. View Article : Google Scholar : PubMed/NCBI | |
Morita K, Shirabe K, Taketomi A, Soejima Y, Yoshizumi T, Uchiyama H, Ikegami T, Yamashita Y, Sugimachi K, Harimoto N, et al: Relevance of microRNA-18a and microRNA-199a-5p to hepatocellular carcinoma recurrence after living donor liver transplantation. Liver Transpl. 22:665–676. 2016. View Article : Google Scholar : PubMed/NCBI | |
Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, Lee YS, Yen TC and Hsieh SY: MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma. J Hepatol. 57:584–591. 2012. View Article : Google Scholar : PubMed/NCBI | |
Wojcicka A, Swierniak M, Kornasiewicz O, Gierlikowski W, Maciag M, Kolanowska M, Kotlarek M, Gornicka B, Koperski L, Niewinski G, et al: Next generation sequencing reveals microRNA isoforms in liver cirrhosis and hepatocellular carcinoma. Int J Biochem Cell Biol. 53:208–217. 2014. View Article : Google Scholar : PubMed/NCBI | |
Shen J, Siegel AB, Remotti H, Wang Q and Santella RM: Identifying microRNA panels specifically associated with hepatocellular carcinoma and its different etiologies. Hepatoma Res. 2:151–162. 2016. View Article : Google Scholar : PubMed/NCBI | |
Lou W, Liu J, Ding B, Chen D, Xu L, Ding J, Jiang D, Zhou L, Zheng S and Fan W: Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC. J Transl Med. 17:72019. View Article : Google Scholar : PubMed/NCBI | |
Murakami Y, Kubo S, Tamori A, Itami S, Kawamura E, Iwaisako K, Ikeda K, Kawada N, Ochiya T and Taguchi YH: Comprehensive analysis of transcriptome and metabolome analysis in Intrahepatic Cholangiocarcinoma and hepatocellular carcinoma. Sci Rep. 5:162942015. View Article : Google Scholar : PubMed/NCBI | |
Ghosh A, Ghosh A, Datta S, Dasgupta D, Das S, Ray S, Gupta S, Datta S, Chowdhury A, Chatterjee R, et al: Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma. Int J Cancer. 138:2732–2744. 2016. View Article : Google Scholar : PubMed/NCBI | |
Peng H, Ishida M, Li L, Saito A, Kamiya A, Hamilton JP, Fu R, Olaru AV, An F, Popescu I, et al: Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma. Oncotarget. 6:5666–5677. 2015. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Wen DY, Zhang R, Huang JC, Lin P, Ren FH, Wang X, He Y, Yang H, Chen G and Luo DZ: A preliminary investigation of PVT1 on the effect and mechanisms of hepatocellular carcinoma: Evidence from clinical data, a meta-analysis of 840 cases and in vivo validation. Cell Physiol Biochem. 47:2216–2232. 2018. View Article : Google Scholar : PubMed/NCBI | |
Shi J, Ye G, Zhao G, Wang X, Ye C, Thammavong K, Xu J and Dong J: Coordinative control of G2/M phase of the cell cycle by non-coding RNAs in hepatocellular carcinoma. PeerJ. 6:e57872018. View Article : Google Scholar : PubMed/NCBI |